Search Results - "BOWMAN, Lee"

Development of a Disease-Specific Version of the EQ-5D-5L for Use in Patients Suffering from Psoriasis: Lessons Learned from a Feasibility Study in the UK by Swinburn, Paul, MRes, Lloyd, Andrew, DPhil, Boye, K.S., PhD, Edson-Heredia, Emily, MPH, Bowman, Lee, PhD, Janssen, Bas, PhD

“…Abstract Objectives The EuroQol five-dimensional (EQ-5D) questionnaire is a generic measure widely used for the assessment of health status. Research has…”
Get full text

Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2− metastatic breast cancer by Cuyun Carter, Gebra, Sheffield, Kristin M., Gossai, Anala, Huang, Yu-Jing, Zhu, Yajun Emily, Bowman, Lee, Nash Smyth, Emily, Mathur, Raina, Cohen, Aaron B., Rasmussen, Erik, Balakrishna, Shreya, Morato Guimaraes, Claudia, Rybowski, Sarah, Seidman, Andrew D.

“…This retrospective observational study described baseline characteristics, real-world treatment patterns, and outcomes among patients with metastatic breast…”
Get full text

A simple and reliable method for determination of optimum pH in coupled enzyme assays by Bowman, Lee, Motamed, Rachael, Lee, Paul, Aleem, Kadijah, Berawala, Astha S, Hayden, Katherine L, Bzik, David J, Chattopadhyay, Debasish

“…Determination of the optimum pH in a coupled enzyme assay poses significant challenges because altering the pH of the reaction mixture can affect the…”
Get full text

Estimating the Cost of Cancer: Results on the Basis of Claims Data Analyses for Cancer Patients Diagnosed With Seven Types of Cancer During 1999 to 2000 by CHANG, Stella, LONG, Stacey R, KUTIKOVA, Lucie, BOWMAN, Lee, FINLEY, Denise, CROWN, William H, BENNETT, Charles L

“…Cancer accounts for 60.9 billion dollars in direct medical costs and 15.5 billion dollars for indirect morbidity costs. These estimates are derived primarily…”
Get full text

The economic burden of lung cancer and the associated costs of treatment failure in the United States by Kutikova, Lucie, Bowman, Lee, Chang, Stella, Long, Stacey R., Obasaju, Coleman, Crown, William H.

“…The economic burden of lung cancer was examined with a retrospective case-control cohort study on a database containing inpatient, outpatient and drug claims…”
Get full text

Medical and productivity costs of anxiety disorders: Case control study by Marciniak, Martin, Lage, Maureen J., Landbloom, Ronald P., Dunayevich, Eduardo, Bowman, Lee

“…This retrospective case‐control study examines the medical and productivity costs associated with a diagnosis of anxiety. The study used a data set from a…”
Get full text

The Effect of Self-Reported and Performance-Based Functional Impairment on Future Hospital Costs of Community-Dwelling Older Persons by Reuben, David B., Seeman, Teresa E., Keeler, Emmett, Hayes, Risa P., Bowman, Lee, Sewall, Ase, Hirsch, Susan H., Wallace, Robert B., Guralnik, Jack M.

“…Purpose: We determined the prognostic value of self-reported and performance-based measurement of function, including functional transitions and combining…”
Get full text

Quality of Life Analysis in Patients with Retinitis Pigmentosa by Humphries, Audrey, Bowman, Lee, Nguyen, Timothy, So, Joshua, Duff, Madison, Grover, Sandeep, Chen, Jinghua

“…Retinitis pigmentosa (RP) is a chronic progressive disease causing loss of visual acuity and ultimately blindness. This visual impairment can contribute to…”
Get full text

Clinical and Genomic Characteristics of Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors by Rao, Xi, Chen, Yongmei, Beyrer, Julie, Nash Smyth, Emily, Morato Guimaraes, Claudia, Litchfield, Lacey M, Bowman, Lee, Lawrence, Garreth W, Aggarwal, Amit, Andre, Fabrice

“…We explored the clinical and genomic characteristics of hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC) after progression…”
Get full text

Abstract P1-18-37: Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 and 6i for HR+, HER2- MBC in the real world by Kalinsky, Kevin M, Kruse, Megan, Smyth, Emily Nash, Guimaraes, Claudia M, Gautam, Santosh, Nisbett, Alnecia R, Fisher, Maxine D, Cui, Zhanglin Lin, Bowman, Lee

“…Abstract Background: Cyclin-dependent kinase 4 and 6 inhibitors (CDK4 & 6i) provide significant benefit for patients (pts) with HR+, HER2- MBC, however,…”
Get full text

Clinicogenomic factors and treatment patterns among patients with advanced non–small cell lung cancer with or without brain metastases in the United States by Smyth, Emily Nash, John, Jincy, Tiu, Ramon V, Willard, Melinda Dale, Beyrer, Julie Kay, Bowman, Lee, Sheffield, Kristin M, Han, Yimei, Brastianos, Priscilla K

“…Abstract Background This retrospective, real-world study evaluated the prevalence of brain metastases, clinicodemographic characteristics, systemic treatments,…”
Get full text

Outcomes for Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States and Japan: A Study of Two Real-World Databases by Rai, Shinya, Hess, Lisa M., Chen, Yongmei, Bowman, Lee, Abada, Paolo B., Konig, Heiko, Walgren, Richard A., Tanizawa, Yoshinori, Cai, Zhihong, Tajimi, Masaomi

“…Background: Patients with mantle cell lymphoma (MCL) have limited treatment options following covalent BTK inhibitor (cBTKi) therapy, with no standard regimens…”
Get full text

Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2− MBC in the real world by Kruse, Megan, Smyth, Emily Nash, Bowman, Lee, Gautam, Santosh, Guimaraes, Claudia M., Nisbett, Alnecia R., Fisher, Maxine D., Cui, Zhanglin Lin, Sheffield, Kristin M., Kalinsky, Kevin

“…Purpose Cyclin Dependent Kinase 4 & 6 inhibitors (CDK4 & 6i) have transformed the management of HR+, HER2− metastatic breast cancer (MBC); however, the optimal…”
Get full text

Characterizing demographics, clinical, and genomic characteristics for U.S. patients with HR+, HER2- metastatic breast cancer following progression on a CDK4 and 6 inhibitor by Andre, Fabrice, Aggarwal, Amit, Rao, Xi, Chen, Yongmei, Beyrer, Julie Kay, Nash Smyth, Emily, Guimaraes, Claudia Morato, Litchfield, Lacey, Bowman, Lee

“…Abstract only 1015 Background: Cyclin-dependent kinases 4 and 6 inhibitors (CDK4 & 6i) have advanced the therapeutic landscape for patients with hormone…”
Get full text

Clinical Characteristics, Treatments, and Concurrent Mutations in Non–Small Cell Lung Cancer Patients With NF1 Mutations by Bowman, Lee, Tiu, Ramon, Smyth, Emily Nash, Willard, Melinda Dale, Li, Li, Beyrer, Julie, Han, Yimei, Singh, Ambrish

“…Metastatic non–small cell lung cancer (mNSCLC) is characterized by complex genomic alterations. NF1 mutations may confer distinct clinical characteristics…”
Get full text

Poster: MCL-041: Outcomes for Recurrent Mantle Cell Lymphoma Post-BTK Inhibitor Therapy in Japan: An Administrative Database Study by Rai, Shinya, Tanizawa, Yoshinori, Cai, Zhihong, Tajimi, Masaomi, Asou, Hiroya, Huang, Yu-Jing, Taipale, Kaisa, Bowman, Lee

Get full text

MCL-041: Outcomes for Recurrent Mantle Cell Lymphoma Post-BTK Inhibitor Therapy in Japan: An Administrative Database Study by Rai, Shinya, Tanizawa, Yoshinori, Cai, Zhihong, Tajimi, Masaomi, Asou, Hiroya, Huang, Yu-Jing, Taipale, Kaisa, Bowman, Lee

“…No standard drug therapies are currently available after covalent BTK inhibitor (BTKi; ibrutinib) treatment of patients with mantle cell lymphoma (MCL). We…”
Get full text

Genomic characterization of lung tumors and metastatic (Met) sites in advanced (Adv) NSCLC by Willard, Melinda D, Nash Smyth, Emily Nash, Tiu, Ramon Velasquez, Beyrer, Julie, Zhu, Yajun Emily, Bowman, Lee, Sheffield, Kristin M, Han, Yimei, Brastianos, Priscilla

“…Abstract only 2014 Background: Molecular alterations (MA) found in brain (Br) mets of NSCLC pts can differ from primary and/or other met sites, which may…”
Get full text

Clinical characteristics, treatment (Tx) patterns, and overall survival (OS) in advanced (Adv) NSCLC patients (Pts) with and without brain metastases (BM) by Nash Smyth, Emily Nash, Tiu, Ramon Velasquez, Willard, Melinda D, Beyrer, Julie, Zhu, Yajun Emily, Bowman, Lee, Sheffield, Kristin M, Han, Yimei, Brastianos, Priscilla

“…Abstract only 2035 Background: BM in NSCLC pts are associated with significant morbidity and mortality. This analysis describes the frequency and timing of BM…”
Get full text

Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer by Smyth, Emily Nash, Shen, Wei, Bowman, Lee, Peterson, Patrick, John, William, Melemed, Allen, Liepa, Astra M

“…Patient-reported outcomes have been associated with survival in numerous studies across cancer types, including breast cancer. However, the Brief Pain…”
Get full text